Table 9A. Feasibility of transporting fresh human tumor 
explants to Somatix for the production of the genetically- 
altered GMCSF-secreting tumor vaccine. Since 5/22/92, 8 
renal cell carcinomas were transported to Somatix for in 
vitro expansion and transduction. The first 3 tumors (RCC 
5.22.92, 6.29.92, 7.20.92) were first mechanically 
dissociated and digested to a single cell suspension at Johns 
Hopkins Oncology Center, and then transported frozen on dry 
ice. The subsequent 5 tumors (8.28.92, 9.14.92, 9.15.92, 
11.30.92, 12.10.92) were initially mechanically dissociated 
into 0.5 cm fragments, then transported on wet ice overnight 
to Somatix. The tumor fragments were enzymatically digested 
approximately 18 hours later at Somatix. The total # of 
viable cells and the last in vitro passage achieved are 
recorded below. The % viability after enzymatic digestion is 
recorded in parenthesis. 
TUMOR CODE 
# VIABLE TUMOR CELLS 
(% VIABILITY) 
LAST PASSAGE 
OBTAINED 
HISTOLOGY 
RCC 
5.22.92 
3.3 
X 
10 7 
P3 
Multicystic, 
grade III, with 
oncocytic 
features 
RCC 
6.29.92 
9.0 
X 
10 6 
P5 
Clear cell, 
grade II 
RCC 
7.20.92 
11.2 
X 
10 8 
P3 
Grade III 
RCC 
8.28.92 
1.2 
X 
10 8 
(67%) 
P5 
Grade II AND III 
Granular cell 
RCC 
9.14.92 
2.2 
X 
10 8 
(88%) 
P2 
Granular cell 
with clear cell 
features 
RCC 
9.15.92 
1.8 
X 
10 7 
(60%) 
P4 
Grade I and II 
RCC 
11.30.92 
6.8 
X 
10 6 
(87%) 
P3, still 
growing 
Oncocytoma 
RCC 
12.10.92 
2.8 
X 
10 8 
(86%) 
P3, Btill 
growing 
Grade II with 
oncocytic 
features 
Recombinant DNA Research, Volume 17 
